Biopharmaceutical industry is concerned, Nanjing 9 projects completed online roadshow

Pharmaceutical Network Industry DynamicRecently, 2020 Nanjing Science and Technology Cloud Investment Biomedicine and Big Health Industry Special Plugand Play China Nanjing Innovation and Entrepreneurship Double Selection Project Roadshow Event was successfully held, a total of 9 biomedical projects for online roadshow, projects covering intelligent diagnosis and treatment, liquid biopsy, gene sequencing, brain neuroengineering, bone technology, rehabilitation medical devices, medical big data mining, artificial intelligence and other fields, Hangzhou Airlines biology is mainly engaged in the invention and production of medical device products, at present, gathered in the brain deep electrical stimulation surgery adjustment, brain interface hardware and software, hand rehabilitation robot, epilepsy early warning system, myoelectric exoskeleton assisting robot and so onThe company's "on the cloud" roadshow shows is the positioning of brain lesions of domestic testing equipment, proposed to jointly Beijing Tiantan Hospital, Shanghai Huashan Hospital, such as related high-tech medical equipment research and development and industrialization layoutBeijing Yi microbiotics have many years of experience in molecular biology, especially proteomics and chip-related fields, this road show is liquid biopsy technologyAccording to the introduction, this technology can improve the accuracy of diagnosis of tumor and other diseases, to achieve early diagnosis of tumors and the treatment of cancer and other diseasesit is understood that the nine projects are technology cloud investment in May 19-26, from nearly 100 recommended projects for selection, and combined with the park industry-oriented preliminary matching after the selectionthe next step, Nanjing Science and Technology Bureau will work with PNP to screen all projects, and with Nanjing Biomedicine Valley, Jiangsu Life Science and Technology Park and other science and technology parks with biomedicine and great health characteristics together to carry out one-on-one in-depth docking, to promote the project to Nanjing to visit the landingbiopharmaceutical industry is known as the "forever sunrise industry", Nanjing is aiming at this field, as one of the leading industries to build, and strive to build hundreds of billions of industrial clustersData show that in 2019, Nanjing's biopharmaceutical industry regulations enterprises achieved a production value of 46.54 billion yuan, an increase of 30.2% year-on-year, of which the number of listed companies in the biopharmaceutical industry reached 10The city currently has 158 biopharmaceutical innovation platform, has become an important support for the development of biopharmaceutical industry innovation in Nanjingat present, the city has formed a biomedicine "one valley, one town, three parks" industrial cluster area, that is, Nanjing Biomedicine Valley (Jiangbei New Area), Nanjing Life Science and Technology Town (Jiangning District), Jiangsu Life Science and Technology Innovation Park (Chixia District), Gaoxian Medical and Health Industry Park, NanjingRaw MaterialsIndustrial Park (Jiangbei New Area), the main business income accounted for more than 75% of the city's biopharmaceutical industryat the same time,, Nanjing initially formed an industry-wide system the cultivation of Chinese herbal medicine
s, the production of raw materials, chemical pharmaceuticals, biopharmaceuticals, traditional Chinese medicine, the outsourcing of research and development services, and medical devices And initially built research and development, incubation, pilot, production, circulation and other biopharmaceutical industry chain, in anti-tumor drugs, cardiovascular drugs, autoimmune disease drugs, gene technology and cell therapy and other fields have certain advantages with the rapid development of the city's biopharmaceutical industry, the policy will also give strong support to the biopharmaceutical industry "Nanjing City to build a biomedicine and health industry landmark action plan" proposed that by 2022, the city's biopharmaceutical industry innovation comprehensive ranking of the top five, biomedicine and health industry scale of more than 100 billion yuan, through strengthening industrial policy innovation, support innovative product applications, to promote investment, to ensure the project land supply, improve investment and financing services and other initiatives to increase the support and innovation incentives for biopharmaceutical industry.